RAPID DETECTION OF PARKINSONS DISEASE W/ ALTROPANE
RAPID DETECTION OF PARKINSONS DISEASE W/ ALTROPANE
批准号:
6277801
负责人:
ALAN J FISCHMAN
金额:
$3.01万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-05-01 至 1999-04-30
中文摘要
帕金森氏病(PD)是一种进行性神经系统疾病,
以多巴胺神经元及其神经变性为特征
来自特定大脑区域的终末,特别是尾状核和
壳核。由于多巴胺神经元含有多巴胺转运体,
退化过程可以通过转运蛋白的丢失来监控
在突触前神经纤维和终末。与之结合的放射性配体
这些位点是早期诊断该病的有希望的探索者。
这可能允许使用药物进行干预,这些药物可以防止
疾病进展或促进再生。多巴胺的成像
终端还可以进一步监测治疗的效果
旨在维持或提高多巴胺活性的方法
神经元。基于之前对阿托品的前景看好的研究(见
神经化学分会摘要1、2、3),I期临床
用[123I]阿托品作为多巴胺神经元探针的试验获得批准
被美国食品和药物管理局。目标是评估以下项目的有效性
阿托品,SPECT(或PET)显像剂,[123I]2-甲氧基-3
-(4-fluorophenyl)-N-(1-iodoprop-1-en-3-yl)nortropane([123I]阿托品)
来检测帕金森氏症。在这项研究中,单光子发射
用[~(123)I]阿托品进行计算机断层扫描(SPECT)
7名健康志愿者(5名男性,年龄)的多巴胺转运体密度
37-75岁和2名女性,年龄分别为26和39岁)和8名男性患者
帕金森病(年龄14-79岁,Hoehn和Yahr分期1.5-3(n=5)和
4~5例(n=3)。动态SPECT图像和动脉血样本
在1.5-2小时内采集,并分析血浆放射性
层析以获得代谢物校正的动脉输入
功能。纹状体(Str)DAT的结合势(BP,B‘max/Kd)
以枕叶皮质(OCC)为例,用两种方法计算部位
参考资料。在第一种方法中,组织时间-活动曲线(TAC)和
代谢物校正的动脉输入功能通过分析
开发了可逆受体配体的线性图解法。在……里面
第二种方法,将表达式(StrTAC-OccTAC)拟合到
伽马变量函数与最大值同时除以OccTAC
用时间估算血压。在5例PD患者中,SPECT数据
与用[18F]6-氟多巴进行正电子发射计算机断层扫描的结果进行比较
(FD-PET)。血浆分析表明[~(123)I]阿托品能迅速
转化为极性代谢物。健康志愿者的SPECT图像
结果表明[~(123)I]阿托品在体内快速、选择性地积累
纹状体,并在术后1小时内产生极好的图像质量
注射。两种分析方法都显示每十年减少7.6%
结合潜力和平均纹状体数值(更正至25岁)
方法1和方法2分别为1.77±0.18和2.00±0.16。
帕金森病患者纹状体明显堆积
减少,损失模式与报告的情况相似
多巴胺,最深的在后壳核,相对较少
尾状核。FD-PET也观察到了类似的模式。
对于整个纹状体,年龄校正的结合潜力显著
(P<;0.001)减少;0.92±0.0 5(方法1),0.92±0.0 6(方法2)。
用这两种方法测得的结合电位值都非常显著。
相似且高度相关的R2=0.88,(p<;0.001)。这些结果
表明[~(123)I]阿托品是一种很好的SPECT显像剂
人脑中的多巴胺转运体/多巴胺神经元。高潮
配体的选择性和快速纹状体积累允许
在不到2小时的时间内准确量化这些站点。结果是
进一步证明[123I]阿托品是一种有效的标记物
帕金森氏症。一期临床试验正在进行中。Bonab
首页--期刊主要分类--期刊细介绍--期刊题录与文摘--期刊详细文摘内容三者的比较
I-123 SPECT定量检测多巴胺转运体的方法
阿托品。SoC。核子。地中海医院。38:949,1997。Fischman AJ,Babich JW
Bonab AA,Alpert NM,ElMaleh DR,Barrow SA,Graham Wa,Meltzer PC,
马德拉斯BK。SPECT快速检测帕金森病
阿托品是多巴胺转运蛋白的选择性配体。SoC。核子。
Med.38:219,1997。Fischman AJ,Bonab AA,Babich JW,Palmer P,Alpert
首页--期刊主要分类--期刊细介绍--期刊题录与文摘--期刊详细文摘内容
英文摘要
Parkinson's disease (PD) is a progressive neurological disorder,
characterized by degeneration of dopamine neurons and their nerve
terminals from specific brain areas, particularly the caudate and
putamen. Since dopamine neurons contain the dopamine transporter, the
degenerative process can be monitored by the loss of the transporter
in presynaptic nerve fibers and terminals. Radioligands that bind to
these sites are promising probes for e arly diagnosis of the disease
which may allow for intervention with drugs that either prevent
disease progression or promote regeneration. Imaging of dopamine
terminals can furthermore monitor the effectiveness of therapeutic
approaches designed to maintain or improve the viability of dopamine
neurons. Based on previous promising research with altropane (see
abstracts 1, 2, 3 of Division of Neurochemistry), a Phase I clinical
trial with [123I]altropane as a probe of dopamine neurons was approved
by the FDA. The objectives were to assess the effectiveness of
altropane, a SPECT (or PET) imaging agent, [123I]2 -carbomethoxy-3
-(4-fluorophenyl)-N-(1-iodoprop-1-en-3-yl)nortropane ([123I]altropane)
to detect Parkinson's disease. In this study, single photon emission
computed tomography (SPECT) with [123I] altropane was used to measure
dopamine transporter density in 7 healthy volunteers (5 males, age
37-75 and 2 females ages 26 and 39) and 8 male patients with
Parkinson's disease (age 14-79, Hoehn and Yahr stage 1.5-3 (n=5) and
4-5 (n=3). Dynamic SPECT images and arterial blood samples were
acquired over 1.5-2 hrs and plasma radioactivity was analyzed
chromatographically to obtain metabolite corrected arterial input
functions. Binding potential (BP, B'max / KD) for striatal (Str) DAT
sites was calculated by 2 methods using occipital cortex (Occ) as a
reference. In the first method, tissue time-activity curves (TAC) and
metabolite corrected arterial input functions were analyzed by a
linear graphical method developed for reversible receptor ligands. In
the second method, the expression (StrTAC - OccTAC) was fitted to a
gamma variate function and the maximum divided by OccTAC at the same
time was used to estimate BP. In 5 of the PD patients the SPECT data
were compared with the results of PET with [18F] 6-fluoro DOPA
(FD-PET). Plasma analysis indicated that [123I]altropane is rapidly
converted to polar metabolites. SPECT images in healthy volunteers
showed that [123I]altropane accumulated rapidly and selectively in the
striatum and yielded excellent quality images within 1 hr after
injection. Both methods of analysis revealed a 7.6%/decade reduction
in binding potential and average striatal values (corrected to age 25)
were 1.77+0.18 and 2.00+0.16 by methods 1 and 2. In all the
Parkinson's diseased patients, striatal accumulation was markedly
reduced and the pattern of loss was similar to that reported for
dopamine, most profound in the posterior putamen with relative sparing
of the caudate nuclei. A comparable pattern was observed with FD-PET.
For total striatum, age corrected binding potential was significantly
(p<0.001) reduced; 0.92 + 0.05 (method 1), 0.92+0.06 (method 2).
Measured by the 2 methods, binding potential values were remarkably
similar and highly correlated r2 = 0.88, (p<0.001). These results
indicate that [123I]altropane is an excellent SPECT ligand for imaging
the dopamine transporter/dopamine neurons in human brain. The high
selectivity and rapid striatal accumulation of the ligand allows for
accurate quantitation of these sites in less than 2 hrs. The results
further demonstrate that [123I]altropane is an effective marker for
Parkinson's disease. A Phase I clinical trial is in progress. Bonab
AA, Babich JW, Alpert N, Madras BK, Fischman AJ. Comparison of three
methods of quantification of dopamine transporters by SPECT with I-123
altropane. Soc. Nucl. Med. 38:949, 1997. Fischman AJ, Babich JW,
Bonab AA, Alpert NM, Elmaleh DR, Barrow SA, Graham WA, Meltzer PC,
Madras BK. Rapid detection of Parkinson's disease by SPECT with
altropane a selective ligand for dopamine transporters. Soc. Nucl.
Med.38:219, 1997. Fischman AJ, Bonab AA, Babich JW, Palmer P, Alpert
NM, Elmaleh DR, Barrow SA, Graham W, Meltzer PC, Hanson RH, Madras BK.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金